|Awarded On||February 21, 2019|
|Title||A Randomized, Controlled Trial Comparing the Immunogenicity of 2 Doses Versus 3 Doses of the 9-Valent HPV Vaccine in Males and Females 15 to 26 Years of Age|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||The University of Texas Medical Branch at Galveston|
|Principal Investigator/Program Director||Abbey Berenson|
|Cancer Sites||Cervix Uteri, Head and Neck, Penis|
*Pending contract negotiation
The HPV vaccine is recommended for all adolescents and young adults to prevent several types of cancer. If the vaccine series is started by 14 years of age, only 2 doses are recommended. However, if the vaccine series is started at age 15 or greater, 3 doses are recommended. It is possible that 2 doses are actually sufficient in older teens and young adults, but no one has tested this hypothesis to see if it is true. We will conduct a clinical trial to examine the immune response of older teens and young adults who receive 3 doses of the HPV vaccine as compared to the immune response of those who receive only 2 doses. We hypothesize that the immune responses will be similar, demonstrating th...